Overview
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that was developed to isolate the fat-loss effects of GH without the growth-promoting or diabetogenic effects. Originally developed by Monash University in Australia, it mimics the way natural GH regulates fat metabolism. It has been approved in Australia as a food supplement ingredient.
Mechanism of action
AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the lipolytic fragment of human growth hormone. It acts on beta-3 adrenergic receptors in adipose tissue. Unlike full-length GH, it does not increase IGF-1 levels, affect blood glucose, or promote tissue growth — isolating the fat-metabolizing mechanism.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| fat loss | subcutaneous | 250–500 mcg | daily | Inject in the morning on an empty stomach. 12-week cycles. Often combined with dietary modification. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Phase IIb clinical trials showed modest weight loss versus placebo (~2.6kg over 12 weeks) but failed to meet endpoints for Phase III. Despite the mixed clinical data, the peptide gained popularity in wellness clinics. Australian TGA approved it as a food supplement ingredient. Animal studies show significant fat reduction without affecting growth or glucose metabolism. Safety profile is favorable with no significant adverse events in clinical trials.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Legal status
Under FDA reclassification review. Approved in Australia as a complementary medicine ingredient. Available from compounding pharmacies in several countries.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.